Navigation Links
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was conducted in subjects with acute ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The presentation was made in a poster session at the American College of Cardiology (ACC) 56th Annual Scientific Session in New Orleans, Louisiana. INO-1001 is an inhibitor of poly(ADP-Ribose) polymerase (PARP), a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and is being studied as a treatment for certain acute cardiovascular conditions and cancer. Additionally, PARP inhibition shows promise in inflammatory disorders. PARP's role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1).

"Whereas advances in pharmacologic and mechanical reperfusion therapy have improved the outcomes of patients with STEMI, reperfusion injury, which is associated with severe damage to the cardiac tissue, is a significant complication that has no current safe and effective treatment options," commented Dr. Andrew Salzman, Inotek's President and CEO. "These Phase 2 data provide further support for our PARP inhibitor program in cardiovascular disease. These results combined with existing preclinical data suggest that INO-1001 produces significant PARP inhibition and has the potential to protect cardiac tissue from damage."

Researchers from the Brigham and Women's TIMI Study Group and Inotek Pharmaceuticals reported that plasma from patients treated with INO-1001 suppressed ex vivo PARP activation. This effect was observed up to 24 hours following drug admi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/2/2015)... and VANCOUVER , July 2, ... (TSX-V: EPI) announced today that its common shares have been ... ("NASDAQ") under the symbol "EPIX". ESSA will begin ... retain its listing on the TSX Venture Exchange under the ... of the common shares on the NASDAQ, each of the ...
(Date:7/2/2015)... , July 2, 2015  New product launches ... its leading role in educating thought leaders about new ... can heavily influence how well a new therapy performs ... study from research and consulting leader Best Practices, LLC, ... need to focus on are early stage thought leader ...
(Date:7/2/2015)... N.Y. , July 2, 2015  Before you head ... ahead so you can stay safe and healthy. Take steps ... #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your Skin ... from the sun can increase your risk of skin cancer. ... shade as much as possible, especially during midday hours. Wear ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3
... Food and Drug Administration (FDA) has cleared InTone™, a ... "InTone is a true medical breakthrough, and welcome ... issues," said Herschel "Buzz" Peddicord, president & CEO of ... we believe we can effectively treat this condition in ...
... March 1, 2012  Avaxia Biologics, Inc., a privately-held biotech ... antibody therapeutics for the treatment of gastrointestinal diseases, is ... and CEO, has been was named one of Mass ... Tech,s 9th annual Women to Watch awards recognize women ...
Cached Medicine Technology:Medical Breakthrough for Incontinence From InControl Medical, LLC Cleared by FDA 2Avaxia Biologic's Barbara Fox Named one of Mass High Tech's Women to Watch in 2012 2
(Date:7/4/2015)... ... July 05, 2015 , ... Dating a real millionaire ... the best online millionaire dating service and strives to remove the worries from meeting ... 1 millionaire dating app of 2015 and readers have responded with excitement. ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project ... technical sales expertise from the North American Board of Certified Energy Practitioners (NABCEP®), ... most highly respected and well established national certification organization for renewable energy professionals. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the only ... lead a national chief nursing officer recruitment for Jane Phillips Medical ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is ... Room , the largest network of independent freestanding emergency rooms in the United States. ... of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... study into the effects of Sanfilippo Syndrome type B (MPS ... the brain from the entry of harmful blood-borne substances is ... South Florida researchers identified damage in specific brain structures involved ... Sanfilippo syndromes, all of which are inherited diseases of metabolism. ...
... care information systems is a multibillion dollar industry. The ... to talk to each other regularly attract media comment. However ... Open Source, that could address many of these problems, because ... systems. Now new research by the University of Warwick,s ...
... commonly used to treat chronic constipation. Although hypermagnesemia ... as a side effect of increased intake of ... fatal cases of hypermagnesemia in adults treated with ... to know whether hypermagnesemia can develop in children ...
... venous leg ulcers is good quality nursing care and ... the University of Leeds has shown that ultrasound therapy does ... contrary to what had been expected. Traditional methods of ... just as well, the authors conclude. "The ,healing energy, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, March ... media characters such as Shrek on the package, regardless of ... we,ve probably already guessed: that young children are going to ... one of their favorite characters on it," said Keri Gans, ...
... 2011 With the help of funding from the March ... carbon monoxide may prevent inflammation that triggers preterm labor, analyze ... blood tests to help identify women at risk of preterm ... researchers that will be supported for the next three years ...
Cached Medicine News:Health News:University of South Florida researchers find blood-brain barrier damaged by disease 2Health News:University of South Florida researchers find blood-brain barrier damaged by disease 3Health News:Resaerch finds open-source software is actually more secure for health care IT 2Health News:The safety of daily magnesium oxide treatment for children with chronic constipation 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 3Health News:March of Dimes provides $2.4 million in new funding for preterm birth research 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Nebulizer Small Volume Medication W/Adult Mask PT ... Tee Adapter , ,An advanced ... ,Provide fine particles with a tighter ... conventional nebulizers, ,Our AirLife™ brand Misty ...
Nebulizer Custom Kit...
... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
Medicine Products: